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“We hear only those questions for which  
we are in a position to find answers” 
Friedrich Nietzsche 
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1.1	   Brief	   history	   and	   contemporary	   classification	   of	  
cardiomyopathies.	  
	  
It	   is	   somewhat	  of	   a	  paradox	   that	   cardiologists	   invest	  most	  of	   their	  
time	   treating	   conditions	   that	   only	   secondarily	   affect	   the	   heart	   muscle,	  
due	   to	   coronary	   disease,	   hypertension	   or	   the	   valvular	   abnormalities.	  
Conversely,	  substantially	  less	  time	  and	  resources	  are	  devoted	  to	  the	  large	  
and	   heterogeneous	   family	   of	   diseases	   originated	   primarily	   from	   the	  
myocardium	   –	   the	   cardiomyopathies.	   Although	   less	   prevalent	   than	   the	  
previously	   quoted	   conditions,	   cardiomyopathies	   have	   a	   considerable	  
impact	   on	   the	   community,	   with	   a	   3%	   estimated	   prevalence	  worldwide,	  
generating	   mortality	   and	   morbidity	   preferentially	   in	   the	   young.	  
Furthermore,	   they	   represent	   valuable	   paradigms	   allowing	   translational	  
investigation	  of	   the	  normal	  and	  abnormal	   functions	  of	   the	  myocardium,	  
creating	   opportunities	   for	   the	   development	   of	   novel	   treatment	   with	  
broad	   implications	   for	  all	   kinds	  of	   cardiac	  patients.	  Therefore,	   increased	  
awareness,	   investments	   and	   research	   efforts	   in	   this	   field	   are	   highly	  
desirable.	  	  	  
In	   its	   present	   definition,	   the	   term	   “cardiomyopathy”	   refers	   to	   a	  
myocardial	  disorder,	  often	  genetic	  in	  nature,	  in	  which	  the	  heart	  muscle	  is	  
structurally	  and	  functionally	  abnormal	   in	   the	  absence	  of	  coronary	  artery	  
disease,	   hypertension,	   valvular	   or	   congenital	   heart	   disease	   sufficient	   to	  
cause	   the	  observed	  myocardial	   abnormality.	   This	   term	  was	   first	   used	   in	  
1957	   by	   Brigden,	   who	   described	   a	   group	   of	   uncommon,	   non-­‐coronary	  
myocardial	   diseases	   [1].	   In	   1961	   Goodwin	   defined	   cardiomyopathies	   as	  
“myocardial	  diseases	  of	  unknown	  cause”	  [2].	  He	  described	  three	  different	  
entities,	  namely	   “dilated,	  hypertrophic	  and	   restrictive”,	   terms	  which	  are	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still	  in	  use	  today.	  However,	  only	  in	  the	  70s	  and	  80s,	  following	  the	  advent	  
of	  non-­‐invasive	   imaging,	  such	  as	  M-­‐mode	  and	  2D	  echocardiography,	   the	  
true	   frequency	   and	   spectrum	   and	   of	   cardiomyopathies	   began	   to	   be	  
recognized.	   In	  an	  attempt	  to	  provide	  a	  practical	  framework	  for	  clinicians	  
involved	   in	   the	   care	   of	   these	   patients,	   the	   first	   classification	   of	  
cardiomyopathies	   was	   published	   in	   1980,	   by	   the	   World	   Health	  
Organization	   (WHO)	   and	   International	   Society	   and	   Federation	   of	  
Cardiology	   (ISFC),	   and	   included	   the	   three	  entities	  proposed	  by	  Goodwin	  
[3].	   The	   definition	   of	   “myocardial	   diseases	   of	   unknown	   cause”	   was	  
maintained	   to	   define	   cardiomyopathies,	   as	   opposed	   to	   “specific	   heart	  
muscle	  diseases”,	  comprising	  heart	  diseases	  with	  similar	  phenotypes,	  but	  
due	  to	  an	  identifiable	  cause.	  	  
In	   the	   last	   30	   years,	   progress	   in	   imaging	   techniques	   and	   intensive	  
genetic	   investigation	   have	   produced	   major	   advancements	   in	   our	  
understanding	   of	   the	   causes	   and	   manifestations	   of	   cardiomyopathies	  	  
[4,5],	   and	   new	   nosologic	   entities	   have	   been	   described.	   	   This	   led	   to	   the	  
new	   revision	   of	   the	   classification,	   carried	   out	   in	   1996	   by	   the	  WHO	   and	  
ISFC	  [6].	  Representing	  a	  major	  advancement,	  both	  “arrhythmogenic	  right	  
ventricular	   dysplasia”	   (with	   the	   inappropriate	   term	   “dysplasia”	   later	  
changed	   to	   “cardiomyopathy”)	   and	   a	   group	   of	   “unclassified	  
cardiomyopathies'',	  defined	  as	  “those	  that	  do	  not	  fit	  in	  any	  group”,	  were	  
added	  to	  the	  three	  original	  subgroups.	  The	  definition	  of	  cardiomyopathy	  
was	  changed	  to	  “diseases	  of	  the	  myocardium	  associated	  with	  myocardial	  
dysfunction”.	   Moreover,	   three	   additional	   subgroups	   termed	  
“hypertensive”,	   “valvular”	   and	   “ischemic”	   cardiomyopathies	   were	   -­‐	  
confusingly	   -­‐	   added	   to	   the	   group	   of	   “specific	   heart	  muscle	   diseases”	   in	  
order	   to	   resolve	   a	   terminology	   controversy	   between	   US	   and	   European	  
experts	  [6].	  These	  were	  defined	  as	  cardiac	  conditions	  characterized	  by	  the	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presence	  of	  hypertension,	  coronary	  or	  valvular	  disease,	   in	  a	  degree	  that	  
would	   not	   explain	   the	   magnitude	   of	   LV	   dysfunction	   observed.	  
Nevertheless,	  a	  substantial	  difference	  in	  terminology	  persisted	  on	  the	  two	  
sides	  of	  the	  Atlantic,	  reflecting	  the	  refusal	  of	  these	  fine	  distinctions	  by	  US	  
experts	  [7].	  
In	  2006,	  an	  American	  Historical	  Association	   (AHA)	  panel	  of	  experts	  
published	  a	  scientific	  statement	  on	  the	  “Contemporary	  classification	  and	  
definitions	  of	  Cardiomyopathies”	  [7].	  They	  proposed	  a	  novel	  approach,	  by	  
which	   the	   etiology,	   rather	   than	   the	   phenotype,	   was	   used	   as	   the	   main	  
criterion.	   “Primary”	   cardiomyopathies	   were	   defined	   as	   those	   “involving	  
only	   the	   heart”,	   as	   opposed	   to	   the	   “secondary”.	   Primary	  
cardiomyopathies	   for	   the	   first	   time	  also	   included	  “ion	  channel	  diseases”	  
and	   were	   differentiated	   in	   three	   subgroups	   based	   on	   their	   etiology	   as	  
“genetic,	  mixed	  and	  acquired”	  [Figure	  1.1-­‐1].	  	  
	  
Figure	  1.1-­‐1:	  American	  Heart	  Association	  classification	  of	  the	  
cardiomyopathies	  	  (2006)	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Of	  note,	  the	  term	  “primary”	  was	  used	  to	  describe	  diseases	  in	  which	  
the	  heart	  is	  the	  sole	  or	  predominantly	  involved	  organ,	  while	  “secondary”	  
described	  diseases	   in	  which	  myocardial	  dysfunction	   is	  part	  of	  a	  systemic	  
disorder	   [5].	   However,	   the	   challenge	   of	   distinguishing	   primary	   and	  
secondary	   disorders	   is	   illustrated	   by	   the	   fact	   that	  many	   of	   the	   diseases	  
classified	   as	   primary	   cardiomyopathies	   can	   be	   associated	   with	   major	  
extra-­‐cardiac	   manifestations;	   conversely,	   pathology	   in	   many	   of	   the	  
diseases	   classed	   as	   secondary	   cardiomyopathies	   can	   predominantly	   (or	  
exclusively)	  involve	  the	  heart.	  	  
The	  radical	  shift	  from	  a	  phenotypic	  to	  an	  etiological	  classification,	  as	  
well	   as	   the	   inclusion	   of	   ion	   channel	   diseases	   among	   cardiomyopathies,	  
although	  proposed	   for	   research	   rather	   than	   clinical	   purposes,	   sparked	  a	  
passionate	  transatlantic	  debate,	  culminating	  in	  a	  thorough	  re-­‐visitation	  of	  
the	   original	   1995	   classification	   by	   the	   European	   Society	   of	   Cardiology	  
(ESC)	  Working	  Group	  on	  Myocardial	  and	  Pericardial	  diseases,	  in	  2008	  [8].	  
Intrinsically	  faithful	  to	  the	  concept	  of	  classifying	  cardiomyopathies	  based	  
on	  phenotype,	   the	   2008	   European	   classification	  maintained	  each	  of	   the	  
time-­‐honoured	  categories	   including	  dilated,	  hypertrophic,	  restrictive	  and	  
arrhythmogenic	   right	   ventricular	   cardiomyopathy.	   The	   confusing	  
“hypertensive'',	   “valvular''	   and	   “ischemic''	   categories	   were	   removed.	   In	  
the	   “unclassified”	   subgroup,	   “Left	   Ventricular	   Non-­‐compaction”	   and	  
“Tako-­‐Tsubo”	   cardiomyopathy	   made	   their	   official	   debut	   [Figure	   1.1-­‐2].	  
Conversely,	   ion	   channel	   diseases	   were	   excluded,	   despite	   their	   genetic	  
nature,	   in	   view	   of	   their	   lack	   of	   a	   structural	   cardiac	   phenotype.	   	   Each	  
cardiomyopathy	   subtype	   was	   subdivided	   in	   a	   familial	   and	   non-­‐familial	  
subset,	   and,	   to	   replace	   the	   pre-­‐genetic	   era	   concept	   of	   “unknown	  
etiology”,	  a	  list	  of	  potential	  genetic	  and	  non-­‐genetic	  causes	  was	  provided	  
[Tables	  1	  to	  5].	  	  





Figure	  1.1-­‐2:	  ESC	  classification	  of	  the	  cardiomyopathies	  (2008)	  
	  
Table	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  table	  5:	  Genetic	  and	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  causes	  of	  cardiomyopathies	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The	  precise	  identification	  of	  the	  disease	  etiology	  has	  obvious	  clinical	  
implications,	   by	   virtue	   of	   its	   direct	   impact	   to	   totally	   different	  
management.	   For	   example,	   amyloidosis,	   Anderson	   Fabry	   diseases	   and	  
glycogen	   storage	   diseases	   may	   be	   diagnosed	   as	   hypertrophic	  
cardiomyopathy	   (HCM);	   yet	   their	   treatment	   varies	   widely.	   Of	   note,	   the	  
inclusion	   of	   amyloidosis	   in	   this	   classification	   was	   widely	   debated	   [9].	  
Substantial	   doubts	   also	   regarded	   Takotsubo,	   a	   disease	   that	   is	   generally	  
transient,	  has	  no	  proven	   inherited	  cause,	  and	  appear	  related	  to	  regional	  
myocardial	   hypoperfusion	   rather	   than	   to	   heart	   muscle	   abnormalities.	  
Ultimately,	  both	  were	  included	  as	  this	  was	  felt	  to	  be	  conceptually	  useful	  
in	  clinical	  practice.	  	  
To	  follow	  is	  a	  brief	  overlook	  of	  the	  major	  cardiomyopathies	  subtypes,	  
based	  on	  contemporary	  definitions.	  	  
	  
1.1.1	   Hypertrophic	  Cardiomyopathy	  
HCM	   is	   a	   genetic	   disease	   characterized	   by	   unexplained	   LV	  
hypertrophy,	   associated	   with	   non-­‐dilated	   ventricular	   chambers,	   in	   the	  
absence	  of	  another	  cardiac	  or	  systemic	  disease	  capable	  of	  producing	  that	  
degree	  of	  hypertrophy	  [Figure	  1.1-­‐3].	  HCM	  is	  diagnosed	  by	  a	  maximal	  LV	  
wall	  thickness	  greater	  than	  15	  mm,	  based	  on	  echocardiography	  (Echo)	  or	  
cardiac	  magnetic	   resonance	   (CMR)	   [10].	   This	   value	   is	   lowered	   to	   13-­‐14	  
mm,	   when	   family	   members	   are	   screened.	   In	   children,	   a	   wall	   thickness	  
greater	   than	   2	   standard	   deviations	   (SD)	   for	   age,	   sex	   or	   body	   size	   is	  
considered	  diagnostic.	  	  




Figure	  1.1-­‐3:	  Figure	  3.	  Hypertrophic	  cardiomyopathy.	  	  
Echocardiographic	   and	   cardiac	   magnetic	   resonance	   images	   from	   a	   17-­‐	  
year	  old	  female	  patient	  with	  HCM.	  Parasternal	   long	  and	  short	  axis	  views	  
show	   severe	   LV	   thickness	   values	   (max	   LV	   wall	   thickness	   31	   mm),	   with	  
redundant	  mitral	  leaflets	  (panels	  A,	  B	  and	  D)	  and	  small	  cavity	  size.	  Apical	  
4	   chambers	   views	   show	   massive	   hypertrophy	   of	   the	   septum	   and	   the	  
antero-­‐lateral	   wall	   (panels	   C	   and	   E).	   Images	   of	   late	   gadolinium	  
enhancement	  showing	   limited	  and	  nontransmural	  area	  of	   fibrosis	  of	   the	  
IVS	  (panel	  F:	  black	  arrow).	  	  
	  
The	   distribution	   of	   hypertrophy	   is	   usually	   asymmetric	   and	  
sometimes	   confined	   to	   one	   or	   two	   LV	   segments.	   As	   a	   consequence,	   LV	  
mass	   (measured	   by	   CMR)	   can	   be	   within	   the	   normal	   range.	   LV	   outflow	  
tract	   obstruction	   is	   an	   important	   feature	   of	   HCM,	   and	   may	   be	  
demonstrated	   in	   up	   to	   70%	  patients	   [11].	  Overall,	   the	   clinical	   course	   of	  
patients	  with	  HCM	   is	   relatively	  benign,	  with	  an	  annual	  mortality	   rate	  of	  
about	  1%.	  Contrary	  to	  prior	  perceptions,	  the	  risk	  of	  sudden	  cardiac	  death	  
is	   relatively	   low	   [12],	  although	  still	  a	  major	  concern	   in	  young	   individuals	  
and	  athletes.	   Furthermore,	   about	  half	   of	   patients	   show	   some	  degree	  of	  
disease	  progression	  and	  functional	  limitation,	  with	  a	  small	  but	  significant	  
subset	   of	   about	   5%	   developing	   the	   so-­‐called	   end-­‐stage	   HCM.	   Family	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screenings,	   following	   the	   introduction	   of	   genetic	   testing,	   has	   led	   to	   the	  
identification	   of	   genotype-­‐positive/phenotype-­‐negative	   individuals,	   a	  
novel	  category	  within	  the	  HCM	  spectrum,	  characterized	  by	  absence	  of	  LV	  
hypertrophy,	  assessed	  by	  ECG	  and	  ECHO	  [10].	  
Sarcomeric	   gene	   mutations,	   often	   private,	   are	   the	   most	   frequent	  
cause	   of	   HCM,	   accounting	   for	   approximately	   30-­‐65%	   of	   probands	   in	  
different	   cohorts	   [13].	   In	   the	   remaining	   subset	   the	   genetic	   substrate	   is	  
unknown.	   Furthermore,	   a	   small	   proportion	   of	   patients	   with	   the	   HCM	  
phenotype	  are	  affected	  by	  cardiofacial	  syndromes	  (e.g.	  Noonan,	  LEOPARD,	  
Costello),	  neuromuscular	  diseases	  (e.g.	  Frederich's	  ataxia),	  mitochondrial	  
diseases	   [14],	   metabolic	   disorders	   of	   lysosomal	   storage	   diseases	   (i.e.	  
Fabry,	  Pompe,	  Danon)	  [15].	  These	  rare	  conditions	  sometimes	  exhibit	  an	  X-­‐
linked	  rather	  than	  the	  autosomal	  pattern	  of	  inheritance,	  usually	  observed	  
in	  HCM	  [Table	  1].	  
	  
1.1.2	   Dilated	  cardiomyopathy	  
DCM	  is	  characterized	  by	  LV	  dilatation	  and	  global	  systolic	  dysfunction	  
(EF	  <	  50%),	  in	  the	  absence	  of	  coronary	  artery	  disease	  or	  other	  identifiable	  
causes	  (such	  as	  systemic	  hypertension,	  valve	  disease,	  drugs,	  inflammatory	  
heart	  diseases)	   capable	  of	   causing	   that	  magnitude	  of	   impairment	   [Table	  
2].	   In	   familial	   DCM,	   screening	   of	   first-­‐degree	   relatives	   will	   identify	   the	  
disease	   in	   up	   to	   50%	   [16].	   As	   for	   many	   other	   cardiomyopathies,	   the	  
prevalence	  of	  DCM	  is	  underestimated,	  because	  many	  patients	  may	  have	  a	  
subclinical	  form	  of	  the	  disease,	  which	  may	  be	  difficult	  to	  diagnose	  for	  the	  
lack	   of	   symptoms.	   Familial	   and	   sporadic	   forms	   of	   DCM	   have	   similar	  
morphological	  manifestation	  and	  clinical	  course	  [Figure	  1.1-­‐4].	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However	  some	  gene	  mutations,	  such	  as	  Lamin	  A/C	  seem	  to	  carry	  a	  
more	  adverse	  outcome,	  in	  particular	  for	  sudden	  death	  	  	  [17-­‐19].	  DCM	  is	  a	  
progressive	  disease,	  with	  a	  prognosis	  that,	  although	  improved	  in	  the	  last	  
decades,	   is	   usually	   poor	   due	   to	   heart	   failure,	   atrial	   and	   ventricular	  
arrhythmias,	   stroke	   and	   sudden	   death	   [20].	   In	   patients	   with	   refractory	  
heart	  failure,	  heart	  transplant	  represent	  the	  final	  option.	  The	  low	  yield	  of	  
genetic	  testing	  for	  DCM	  (i.e.	  30%)	  limits	  its	  clinical	  use	  and	  it	  is	  related	  to	  
the	   large	   number	   of	   potentially	   disease-­‐causing	   genes.	   Furthermore,	  
genetic	   mutations	   are	   usually	   private	   and	   the	   interpretation	   of	   the	  
analysis	   results	   may	   be	   difficult	   [16].	   However,	   the	   advent	   of	   new	  
sequencing	  technologies	   is	  probably	  going	  to	  change	  this	  paradox	   in	  the	  
near	  future	  (see	  chapter	  2).	  	  




Figure	  1.1-­‐4:	  Dilated	  cardiomyopathy	  
Echocardiographic	   and	   cardiac	   magnetic	   resonance	   images	   from	   a	   57-­‐
year	   old	   female	   patient	   with	   DCM	   and	   normal	   coronary	   angiogram.	  
Parasternal	   long	  axis	  view	  and	  CMR	   images	  show	  dilated	  LV	   (panels	  A-­‐B	  
and	  E-­‐F),	  with	  severe	  systolic	  dysfunction	  –	  EF	  =	  21%;	  (panel	  C	  =	  diastole,	  
panel	  D	  =	  systole).	  Abbreviations:	  LV	  =	   left	  ventricle,	  RV	  =	  right	  ventricle	  
IVS	  =	  inter-­‐ventricular	  septum.	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1.1.3	   Restrictive	  cardiomyopathy	  
RCM	  is	  defined	  by	  the	  presence	  of	  a	  restrictive	  LV	  physiology,	  with	  
normal	   or	   more	   often	   reduced	   diastolic/systolic	   volumes,	   normal	   wall	  
thickness	   and	   systolic	   function,	   marked	   diastolic	   flow	   impairment	   and	  
biatrial	  dilatation.	  RCMs	  are	  rather	  uncommon,	  although	  their	  prevalence	  
is	   still	   unknown.	   Either	   Amyloid	   Light-­‐chain	   (AL)	   amyloidosis	   or	  
amyloidosis	  due	  to	  transthyretin	  gene	  mutations	  with	  heart	  involvement,	  
often	   cause	   RCM	   [Table	   3]	   [9].	   A	   striking	   subtype	   of	   disease	   with	  
restrictive	   physiology,	   endomyocardial	   fibrosis,	   endemic	   in	   areas	   of	   the	  
African	  continent,	  has	  an	  unknown	  etiology	  and	  very	  poor	  prognosis	  [21].	  
Moreover	  a	  “restrictive	  phenotype”	  may	  be	  part	  of	  the	  clinical	  spectrum	  
of	  end-­‐stage	  HCM	  [22],	  and	  may	  occasionally	  originate	  as	  a	  primary,	  non	  
HCM-­‐related	  phenotype	  from	  sarcomere	  gene	  mutations	  (generally	  in	  the	  
thin	   filament	   protein	   coding	   genes	   –	   see	   chapter	   2).	   RCM	   is	   usually	  
associated	   with	   severe	   functional	   limitation,	   mainly	   related	   to	   the	  
extreme	   diastolic	   dysfunction,	   with	   reduced	   diastolic	   filling	   and	   stroke	  
volume,	  and	  a	  poor	  prognosis	  [23].	  
	  
1.1.4	   Arrhythmogenic	  right	  ventricular	  cardiomyopathy	  
ARVC	   is	   characterized	   by	   fibro-­‐fatty	   replacement	   of	   the	   right	  
ventricular	   myocardium	   and	   ventricular	   arrhythmias	   [24].	   In	   the	   most	  
common	   right-­‐dominant	   form,	   structural	   changes	   may	   be	   absent	   or	  
confined	   to	   a	   localized	   region	   of	   the	   right	   ventricle	   (inflow	   and	  outflow	  
tract,	   right	   ventricular	   apex,	   known	   as	   the	   `triangle	   of	   dysplasia')	   at	   an	  
early	   stage	   [Figure	   1.1-­‐5].	   Progression	   to	   more	   diffuse	   right	   ventricular	  
disease	  and	  LV	  involvement	  (typically	  affecting	  the	  posterior	  lateral	  wall),	  
associated	  with	  ventricular	  systolic	  dysfunction,	  is	  common	  at	  later	  stages	  
[25].	  Ventricular	  arrhythmias	  are	  the	  clinical	  hallmark	  of	  the	  disease,	  but	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atrial	   fibrillation	   may	   also	   occur.	   The	   diagnosis	   of	   ARVC	   is	   often	  
challenging	  for	  the	  cardiologist,	   in	  particular	  during	  the	  early	  “concealed	  
phase”,	   when	   individuals	   are	   still	   asymptomatic	   and	   structural	  
abnormalities	   are	   subtle.	   Predominant	   LV	   disease	   has	   also	   been	  
recognized	   in	   a	   small	   subset	   of	   patients	   of	   about	   5%.	   New	   diagnostic	  
criteria	   with	   higher	   sensitivity	   and	   specificity	   have	   recently	   been	  
published	   [24,26].	   ARVC	   is	   generally	   a	   familial	   disease	   with	   autosomal	  
dominant	   inheritance	   but	   it	   may	   be	   recessive	   when	   associated	   with	  
woolly	  hair	  and	  palmopalmar	  hyperkeratosis	  (eg,	  Naxos	  disease,	  Carvajal	  
syndrome).	  Mutations	   in	   desmosomal	   and	  non-­‐desmosomal	   genes	  have	  
been	   identified,	   but	   interpretation	   of	   their	   pathogenicity	   is	   often	  
challenging	  in	  the	  affected	  individual	  [Table	  4].	  
	  
Figure	  1.1-­‐5:	  Arrhythmogenic	  cardiomyopathy	  
38	   year-­‐old	   female	   with	   diagnosis	   of	   ARVC,	   resuscitated	   from	   out-­‐of-­‐
hospital	   cardiac	   arrest.	   She	   has	   family	   history	   of	   ARVC	   (mother)	   and	  
sudden	   death	   (brother,	   28	   year	   old).	   CMR	   images	   show	   clearly	   wall	  
aneurysms	  within	   the	   so-­‐called	   ``triangle	   of	   dysplasia’’	   (panel	   AC,	  white	  
arrows:	   evident	   systolic	   bulging	   in	   infundibular,	   apical,	   and	   subtricuspid	  
regions	  of	  the	  RV).	  She	  also	  had	  LV	  involvement	  (apex).	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Abbreviations:	   LV	   =	   left	   ventricle,	   RV	   =	   right	   ventricle,	   IVS=	  
interventricular	  septum.	  
	  
1.1.5	   Unclassified	  cardiomyopathies	  
Isolated	  LV	  non-­‐compaction	  (LVNC)	  is	  characterized	  by	  prominent	  LV	  
trabeculae	   and	   deep	   inter-­‐trabecular	   recesses,	   that	   can	   be	   associated	  
with	  LV	  dilatation	  and	  systolic	  dysfunction	  [Figure	  1.1-­‐6].	  	  
	  
Figure	  1.1-­‐6:	  Left	  ventricular	  non	  compaction	  
Isolated	  left	  ventricular	  non-­‐compaction	  in	  a	  45	  year-­‐old	  male,	  with	  mild	  
systolic	   dysfunction	   (EF	   48%),	   ventricular	   arrhythmias	   and	   normal	   LV	  
diameters.	  Multiple	   trabeculations	  and	  recesses	  are	  evident,	  particularly	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in	  the	  apex	  and	  the	  free	  wall	  of	  the	  LV	  (panels	  A	  and	  C:	  apical	  4	  chambers	  
view;	   panels	   B	   and	   D:	   apical	   3	   chambers	   view).	   CMR	   confirmed	   the	  
diagnosis	   (panels	   E-­‐F).	   Abbreviations:	   LV=	   left	   	   ventricle,	   RV	   =	   right	  
ventricle	  IVS	  =	  inter-­‐ventricular	  septum.	  
LVNC	   is	   familial,	   with	   25%	   of	   asymptomatic	   first-­‐degree	   relatives	  
having	   some	   echocardiographic	   abnormalities	   [Table	   5].	   Of	   note,	   this	  
rather	   mysterious	   disease	   shows	   substantial	   phenotypic	   overlap	   with	  
other	  cardiomyopathies	  (in	  particular	  HCM	  and	  DCM,	  which	  often	  exhibit	  
limited	   areas	   of	   non-­‐compaction	   in	   the	   left	   ventricle),	   as	   well	   as	   a	  
common	   genetic	   substrate	   [8].	   Furthermore,	   LVNC	   may	   be	   associated	  
with	  congenital	  cardiac	  disorders	   (such	  as	  Ebstein's	  anomaly	  or	  complex	  
cyanotic	  heart	  disease)	  and	  some	  neuromuscular	  diseases.	  Therefore,	  it	  is	  
still	   debated	   whether	   isolated	   LVNC	   should	   be	   considered	   a	   separate	  
clinical	   and	   genetic	   entity,	   or	   a	   morphological	   trait	   shared	   by	   many	  
distinct	   cardiomyopathies.	   As	   a	   result	   of	   the	   difficult	   comprehension	   of	  
this	   clinical	   entity,	   the	   real	   prevalence	  of	   LVNC	  and	   its	   outcome	   remain	  
largely	  unknown.	  
Takotsubo	   cardiomyopathy,	   also	   known	   as	   LV	   apical	   ballooning	   or	  
stress-­‐induced	   cardiomyopathy,	   is	   characterized	   by	   transient	   regional	  
systolic	   dysfunction	   involving	   the	   apex	   and/or	   mid-­‐ventricle	   in	   the	  
absence	   of	   obstructive	   coronary	   artery	   disease	   on	   angiogram	   [8].	   The	  
condition	  is	  reported	  all	  over	  the	  world,	  and	  most	  reported	  cases	  occur	  in	  
post-­‐menopausal	  women	  following	  physical	  or	  psychological	  stress,	  but	  it	  
has	   been	   described	   also	   in	   patients	   with	   intracranial	   haemorrhage	   or	  
other	   acute	   cerebral	   accidents	   (so-­‐called	   “neurogenic	   myocardial	  
stunning”).	  Typically,	  takotsubo	  cardiomyopathy	  has	  a	  sudden	  onset,	  with	  
chest	  pain,	  diffuse	  T-­‐wave	   inversion	  and	  mild	   cardiac	  enzyme	  elevation.	  
Symptoms	   are	   often	   preceded	   by	   emotional	   or	   physical	   stress.	   If	   the	  
patient	   survives	   the	   acute	   phase	   of	   disease,	   the	   prognosis	   is	   almost	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invariably	  favourable,	  with	  a	  normalization	  of	  LV	  function	  over	  a	  period	  of	  
days	  to	  weeks;	  recurrence	  is	  possible,	  but	  rare.	  
	  
1.1.6	   A	  never-­‐ending	  story	  
As	   more	   families	   with	   cardiomyopathies	   are	   genotyped,	   and	   new	  
diseases	   are	   being	   described,	   the	   paradigm	   “one	   gene,	   one	   disease”	  
appears	  no	  longer	  sustainable.	  The	  same	  mutation	  can	  be	  expressed	  at	  a	  
different	   age	   and	   give	   rise	   to	   hugely	   different	   phenotypes	   within	   the	  
same	  family.	  Different	  phenotype	  patterns	  may	  originate	  from	  the	  same	  
genetic	   substrates,	   in	   a	   spectrum	   encompassing	   HCM,	   DCM,	   RCM	   and	  
LVNC	   (all	   associated	   with	   sarcomere	   genes),	   or	   ARVC/DCM	   (associated	  
with	   desmosomal	   genes).	   Such	   heterogeneity	   is	   thought	   to	   derive	   from	  
the	   interaction	  between	  one	  or	  more	  genetic	  mutations,	  modifier	  genes	  
and	   environmental	   factors	   [10].	   When	   genetic	   analysis	   is	   performed	   in	  
candidate	   genes,	   the	   probability	   of	   identifying	   the	   pathogenic	   gene	  
mutation	   is	   in	   the	   range	   of	   40	   60%,	   for	   patients	   with	   HCM,	   with	  
approximately	   5%	   of	   complex	   mutations	   [11,12].	   Results	   for	   dilated	  
cardiomyopathy	  (DCM),	  restrictive	  cardiomyopathy	  (RCM)	  and	  isolated	  LV	  
non-­‐compaction	   are	   considerably	   less	   rewarding	   [10],	   although	   the	  
advent	   of	   next	   generation,	   genome-­‐wide	   techniques	   may	   increase	   the	  
yield	   substantially,	   as	   recent	   data	   on	   titin	   in	   DCM	   suggests	   [27].	   The	  
recent	   introduction	   of	   next	   generation	   sequencing	   has	   started	   what	  
promises	  to	  be	  a	  revolution	   in	  molecular	  diagnostics,	  allowing	  rapid	  and	  
affordable	   testing	  of	  hundreds	  of	  genes,	  or	  even	  whole	  genomes.	  As	  an	  
example,	   a	   wide	   range	   of	   truncating	   gene	   mutations	   encoding	   Titin,	   a	  
very	   large	  cytoskeleton	  gene	  which	  could	  not	  be	  assessed	  by	   traditional	  
sequencing	   techniques,	   has	   recently	   been	   discovered	   to	   represent	   a	  
prevalent	  cause	  of	   familial	  DCM,	  up	  to	  25%	  [27].	   In	   the	  near	   future,	   the	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list	  of	   causative	  genes	  will	   therefore	   likely	   require	  an	  update.	  The	   focus	  
for	   researchers	   will	   necessarily	   shift	   from	   analyzing	   single	   mutations	   in	  
candidate	   genes,	   to	   interpreting	   the	   hundreds	   of	   variants	   of	   unknown	  
significance	   in	   putative	   causative	   as	   well	   as	   modifier	   genes,	   requiring	  
entirely	   new	   skills	   and	   significant	   interaction	   with	   biophysicists	   and	  
computer	  scientists.	  	  
At	   present,	   and	   in	   the	   foreseeable	   future,	   however,	   clinical	  
classifications	   of	   cardiomyopathies	   based	   on	   clinical	   presentation	   and	  
morphological	  criteria	  represent	  an	  important	  tool	  for	  clinicians	  involved	  
with	  these	  complex	  diseases.	  While	  calling	  for	  constant	  improvement	  and	  
update	   in	   the	   light	  of	  advances	  provided	  by	   imaging,	   genetics	  and	  basic	  
science,	   individual	  patient	  phenotypes	  continue	  to	  represent	  the	  core	  of	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1.2	   A	   thousand	   conditions	   with	   a	   lot	   in	   common.	  
Translational	   overview	   supporting	   a	   comprehensive	  
approach	  to	  primary	  diseases	  of	  the	  myocardium.	  
	  
The	  pathophysiology	  of	  cardiomyopathies	  is	  extraordinarily	  complex	  
and	  encompasses	  a	  constellation	  of	  different	  mechanisms,	  most	  of	  which	  
at	  present	  unresolved.	  Even	  when	  the	  disease	  model	  is	  narrowly	  defined	  
and	   recognizes	   a	   well-­‐defined	   etiology,	   such	   as	   a	   gene	   mutation,	   the	  
processes	   leading	   to	   the	   phenotypic	   manifestations	   are	   largely	   beyond	  
our	  current	  understanding.	  For	  example,	  early	  hopes	  of	  establishing	  strict	  
genotype-­‐phenotype	  correlations	  in	  HCM,	  probably	  the	  most	  extensively	  
studied	  disease	  in	  this	  group,	  have	  definitely	  been	  abandoned.	  Even	  when	  
the	   link	   between	   mutations	   and	   myocardial	   damage	   is	   relatively	  
understood,	   as	   in	   Anderson	   Fabry	   disease,	   the	   reasons	   of	   clinical	  
heterogeneity	   observed	   even	   among	   individuals	   from	   the	   same	   family	  
remain	  obscure.	   It	   is	  now	  well	  established	  that	  the	  same	  genes	  can	  give	  
rise	   to	   radically	   different	   phenotypic	   and	   clinical	   manifestations	   and	   –	  
conversely	   –	   that	   the	   same	   phenotype	   can	   be	   caused	   by	   mutations	   in	  
different	   genes.	   In	   other	   words,	   gene	  mutations	   are	   necessary	   but	   not	  
sufficient	  to	  cause	  clinical	  phenotypes,	  and	  what	  comes	  in	  between	  is	  at	  
least	   as	   important	   as	   the	   etiology	   itself.	   In	   what	   may	   seem	   like	   an	  
inextricable	   labyrinth,	   however,	   a	   number	   of	   general	  mechanisms	   seem	  
to	  represent	  common	  pathophysiologic	  determinants	  of	  cardiomyopathy	  
phenotypes.	  While	  not	   specifically	   related	   to	   the	  disease	  etiology,	   these	  
features	  represent	  shared	  pathways	  by	  which	  the	  disease	  becomes	  overt	  
and	   leads	   to	   its	   clinical	   consequences;	   in	   some	   cases	   they	   represent	  
features	  are	  common	  with	  heart	  failure	  due	  to	  any	  cause.	  Any	  attempt	  to	  
comprehensively	  cover	  this	  field	  goes,	  is	  would	  be	  too	  ambitious.	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What	  follows	  is	  an	  overview	  of	  some	  of	  the	  most	  intriguing	  elements	  
characterizing	   cardiomyopathy	   pathophysiology,	   representing	   both	   keys	  
to	   further	   understanding	   of	   the	   “core”	   of	   heart	   muscle	   disease,	   and	  
potential	  targets	  for	  treatment.	  
	  
1.2.1	   Genetic	  and	  post-­‐transcriptional	  mechanisms	  
The	   variable,	   often	   age	   related,	   penetrance	   and	   variable	   disease	  
expression	  suggest	  that	  the	  effects	  of	  cardiomyopathy-­‐causing	  mutations	  
are	  modifiable	   both	   by	  modifier	   genes	   and	   environmental	   factors	   [28].	  
Mutations	  generally	  cause	  single	  amino-­‐acid	  substitutions	  in	  proteins	  that	  
become	   incorporated	   into	   the	   sarcomere	   and	   exert	   their	   pathological	  
effects	  by	  acting	  as	  poison	  peptides	  that	  alter	  normal	  sarcomere	  function	  
in	   a	   concentration	   dependent	   manner.	   Thus,	   homozygous	   mutations,	  
multiple	  mutations,	   and	   compound	   genotypes	   (2	   or	  more	  mutations	   in	  
multiple	   genes)	   often	   result	   into	   earlier	   presentation	   and	   rapid	   disease	  
progression	   	   	   [29-­‐31]:	   this	   has	   been	   shown	   for	   HCM,	   ARVC	   and	   ion	  
channel	  disease.	  An	  exception	  to	  this	  rule	  are	  most	  MYBPC3	  mutations	  in	  
HCM,	  that	  result	  in	  insufficient	  protein	  production	  for	  normal	  sarcomere	  
function	   (haploinsufficiency)	   	   	   [32-­‐33].	   Haploinsufficiency	   can	   be	  
attributed	  to	  cell	  surveillance	  mechanisms,	   including	  nonsense-­‐mediated	  
decay	   of	   mRNA	   transcripts	   that	   contain	   premature	   termination	   codons	  
and/or	   ubiquitin-­‐mediated	   proteasomal	   (UPS)	   degradation	   of	  misfolded	  
proteins.	  It	  remains	  to	  be	  demonstrated	  whether	  impairment	  of	  UPS	  due	  
to	  excess	  degradation	  of	  mutant	  proteins	  may	  trigger	  phenotypic	  onset	  or	  
contribute	   to	  disease	  progression	   	   [34].	   In	  addition,	  differential	   levels	  of	  
activity	   in	   these	   cell	   surveillance	   mechanisms	   may	   explain	   individual	  
heterogeneity	   in	   phenotype,	   eg	   within	   families	   with	   the	   same	   genetic	  
mutation.	   Finally,	   MicroRNAs	   (miRNAs)	   are	   small	   conserved	   RNA	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molecules	   nucleotides	   which	   negatively	   modulate	   gene	   expression	   in	  
animals	   and	   plants.	  MiRNAs	   are	   involved	   in	   a	   variety	   of	   basic	   biological	  
processes,	   for	   example,	   cell	   proliferation	   and	   apoptosis	   and	   stress	  
responses.	  A	  subset	  of	  miRNAs	  are	  either	  specifically	  or	  highly	  expressed	  
in	   cardiac	   muscle,	   providing	   an	   opportunity	   to	   understand	   how	   gene	  
expression	  is	  controlled	  by	  miRNAs	  at	  the	  post-­‐transcriptional	  level	  in	  this	  
muscle	  type.	  miR-­‐1,	  miR-­‐133,	  miR-­‐206,	  and	  miR-­‐208	  have	  been	  found	  to	  
be	   muscle-­‐specific,	   and	   thus	   have	   been	   called	   myomiRs;	   among	   their	  
functions,	   they	   have	   been	   shown	   to	   regulate	   cardiac	   development	   and	  
differentiation.	   MiRNAs	   are	   thought	   to	   play	   an	   important	   role	   in	  
modulating	   the	   development	   of	   phenotype	   in	   patients	   with	  
cardiomyopathies.	   For	   example,	   in	   vivo	   miR-­‐133	   levels	   are	   down-­‐
modulated	  in	  patients	  with	  HCM,	  and	  other	  MiRNAs	  have	  been	  implicated	  
in	  the	  regulation	  of	  cardiac	  hypertrophy	  	  [35].	  Therefore,	  both	  the	  initial	  
genetic	  burden	  and	  post-­‐transcriptional	  mechanisms	  seem	  to	  significantly	  
impact	  the	  development	  of	  cardiomyopathies.	  	  
	  
1.2.2	   Abnormal	  calcium	  homeostasis	  
Most	   models	   of	   heart	   failure,	   including	   human	   disease,	   are	  
characterized	   by	   decreased	   SR	   Ca2+-­‐	   ATPase	   (SERCA)	   expression	   and	  
upregulation	   of	   Na+/Ca2+	   exchanger	   (NCX)	   expression	   and	   function.	  
Decreased	   SERCA	   activity,	   by	   slowing	   down	   Ca2+	   reuptake	   to	   the	  
sarcoplasmic	   reticulum,	   allows	  more	   Ca2+	   to	   be	   extruded	   via	   the	   NCX;	  
coupled	  with	  the	  increased	  NCX	  expression	  	  [36]	  this	  results	  in	  a	  net	  loss	  
of	   cell	   Ca2+	   and	   contributes	   to	   the	   reduction	  of	   sarcoplasmic	   reticulum	  
Ca2+	   load	   [37].	  Another	   contributor	   to	   the	   lower	  Ca2+	   content	   in	  heart	  
failure	   is	   the	   increased	   diastolic	   leakage	   of	   Ca2+	   from	   the	   sarcoplasmic	  
reticulum,	  which	  is	  determined	  by	  the	  hyperphosphorylation	  of	  ryanodine	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receptors	  by	  protein-­‐kinase	  A	  and/or	  Ca2+-­‐Calmodulin	  dependent	  protein	  
kinase-­‐II	   (CaMKII)	   [38].	   CaMKII	   activity	   is	   increased	   in	   HF,	   and	   CaMKII-­‐
dependent	   phosphorylation	   of	   RyR	   enhances	   Ca2+	   spark	   frequency	   and	  
thus	  spontaneous	  diastolic	  sarcoplasmic	  reticulum	  Ca2+	  leak	  [39],	  making	  
it	   a	   leading	   pathway	   causing	   contractile	   dysfunction	   and	  
arrhythmogenesis	   in	   HF.	   Enhanced	   NCX	   function,	   combined	   with	   the	  
higher	   probability	   of	   spontaneous	   Ca2+	   release	   from	   the	   SR,	   contribute	  
directly	   to	   arrhythmogenesis	   via	   delayed-­‐afterdepolarizations	   (DADs).	  
When	   a	   large	   spontaneous	   Ca2+	   release	   event	   occurs	   during	   diastole	  
giving	   rise	   to	   a	   generalized	   Ca2+	   wave,	   part	   of	   the	   released	   Ca2+	   is	  
extruded	   through	   the	   NCX,	   which	   generates	   an	   inward	   current	   that	  
depolarizes	  the	  membrane	  (i.e.	  a	  DAD).	  If	  large	  enough,	  a	  DAD	  may	  reach	  
the	   threshold	   for	   a	   premature	  AP,	   giving	   rise	   to	   a	   premature	   activation	  
that	   can	   propagate	   through	   the	   myocardium,	   triggering	   sustained	  
arrhythmias.	  Thus,	  abnormal	  calcium	  homeostasis	   is	  a	  main	  determinant	  
of	  several	  manifestations	  that	  are	  common	  to	  several	  cardiomyopathies,	  
including	   diastolic	   dysfunction	   (due	   to	   the	   excess	   residual	   cytoplasmic	  
Ca2+	  at	  the	  end	  of	  systole),	  impaired	  energetics,	  myocardial	  ischemia	  and	  
arrhythmgenesis.	  This	  has	  been	  specifically	  shown	  in	  models	  and	  human	  
tissue	  with	  HCM,	  for	  example.	  	  
	  
1.2.3	   Lack	  of	  energetic	  sustainability	  	  
Primary	   myocardial	   disease	   is	   often	   characterized	   by	   abnormal	  
energy	   generation	   and/or	   consumption.	   In	   rare	   diseases,	   such	   as	  
cardiomyopathies	   associated	   with	  mitochondrial	   disease,	   this	   feature	   is	  
taken	   to	   the	   extreme.	   However,	   varying	   levels	   of	   energetic	   impairment	  
can	   be	   found	   in	   virtually	   all	   models.	   Notably,	   this	   is	   not	   always	   due	   to	  
insufficient	   energy	   generation;	   in	   HCM	   for	   example,	   disease	   causing	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mutations	   are	   often	   gain-­‐of-­‐function,	   and	   lead	   to	   sarcomere	   energetic	  
inefficiency,	   due	   to	   the	   excess	   ATP	   utilization	   required	   to	   generate	  
isometric	   tension	   	   [40,	   41],	   which	   may	   ultimately	   compromise	   overall	  
cardiomyocyte	   energetic	   balance	   	   [42].	   Energy	   deficiency	   would	   be	  
expected	  to	  reduce	  the	  activity	  of	  membrane-­‐bound	  energy-­‐requiring	  ion	  
transporters,	   potentially	   triggering	   arrhythmias	   and	   contributing	   to	  
diastolic	   dysfunction,	   and	   to	   decrease	   contractile	   reserve.	   In	   addition,	  
cardiomyocyte	   energetic	   compromise	  might	   contribute	   to	   generation	  of	  
pathologic	   hypertrophy	   (and	   potentially	   adverse	   remodeling)	   as	   a	  
consequence	   of	   intracellular	   energy	   sensor	   activation	   [4].	   In	   addition,	  
residual,	   force-­‐generating,	   ATP-­‐consuming	   acto-­‐myosin	   interactions	  
during	   diastole	   lead	   to	   incomplete	   relaxation	   and	   directly	   contribute	   to	  
diastolic	  dysfunction	  while	   increasing	  the	  energetic	  compromise	  of	  HCM	  
myocytes.	   Sarcomeres	   and	   their	   Z-­‐disk	   components	   are	  now	   recognized	  
centers	  of	  mechano-­‐sensation,	  -­‐transmission	  and	  -­‐transduction	  	  	  [43,	  44].	  
Cardiac	   stress	   leads	   to	  mechanical	   and	   chemical	   signals	   which	   remodel	  
sarcomeres	  and	  either	  offset	  or	  exacerbate	   the	   stress.	   In	  HCM	  patients,	  
altered	   sarcomere	  mechanics	  due	   to	   faster	   kinetics	  of	   force	   generation,	  
hypercontractility	  or	   incomplete	   relaxation	  may	   trigger	  hypertrophy	  and	  
adverse	   remodeling.	   That	   this	   may	   represent	   an	   important	   primary	  
mechanism	   is	  supported	  by	  the	  HCM-­‐causing	  role	  of	  mutations	   in	  genes	  
encoding	   Z-­‐disk	   proteins	   	   [45].	   In	   the	   long	   term,	   reduced	   energy	  
production	   or	   inefficient	   utilization	   may	   become	   non-­‐sustainable,	   and	  
directly	   contribute	   to	   a	   vicious	   cycle	   of	   worsening	   cardiomyocyte	  
dysfunction,	   increased	   LV	   wall	   stress,	   increased	   oxygen	   demand	   and	  
further	   energetic	   mismatch,	   leading	   to	   disease	   progression	   and	   heart	  
failure.	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1.2.4	   Electrophysiological	  remodeling	  
The	  fact	  that	  cardiomyopathies	  may	  express	  an	  electrophysiological,	  
as	   well	   as	   structural,	   cellular	   phenotype	   has	   only	   recently	   been	  
appreciated.	   While	   clinicians	   have	   always	   known	   the	   surface	   ECG	  
manifestations	  associated	  with	  each	  disease,	   these	  have	  classically	  been	  
attributed	   to	   macroscopic	   abnormalities	   of	   the	   heart	   such	   as	   disarray,	  
strain,	  hypertrophy	  and	  necrosis.	  However,	  it	  is	  now	  evident	  that	  some	  of	  
these	   manifestations	   (such	   as	   QT	   prolongation)	   and	   even	   the	  
arrhythmogenic	   potential	   associated	  with	   primary	   heart	  muscle	   disease	  
may	  originate	  at	  the	  level	  of	  the	  cardiomyocyte	  sarcolemma.	  Among	  the	  
most	  prominent	  abnormalities	  are	  alterations	  of	   late	  Na+	  current	   in	  HF.	  
Increased	  [Na+]i	   in	  HF	  may	  be	  due	  to	   increased	  Na+	   influx	  or	  decreased	  
Na+	   efflux.	   Early	   studies	   suggested	   that	   an	   excess	   of	   Na+	   influx	   is	   the	  
major	  contributor	  to	  Na+	  overload	  and	  the	  main	  source	  of	  the	  increased	  
Na+	  entry	  is	  the	  enhanced	  “late”	  or	  “persistent”	  Na+	  current	  	  	  [46,	  47].	  As	  
explained	  before,	   a	   component	  of	  Na+	   current	  with	   slow	  or	   incomplete	  
inactivation	   can	   be	   measured	   in	   normal	   human	   and	   animal	   cardiac	  
myocytes	   	   [48].	   However,	   acquired	   and	   primary	   cardiac	   diseases	   are	  
commonly	   characterized	  by	  abnormally	   large	   INaL.	  Enhancement	  of	   late	  
Na+	   current	   has	   been	   identified	   in	   HCM,	   and	   may	   contribute	   to	   its	  
pathogenesis.	   In	  addition,	  besides	  LQT3	  syndrome,	  which	   is	  directly	  due	  
to	  Na+	  channel	  mutations	  [49],	  increase	  INaL	  was	  found	  as	  a	  consequence	  
of	  ankyrin	  B	  mutations	  (LQT4	  syndrome)	  and	  caveolin-­‐3	  mutations	  (LQT-­‐
CAV3)	  	  [50,	  51],	  as	  well	  as	  end	  stage	  heart	  failure	  	  [52,	  53]	  and	  following	  
myocardial	   infarction	   [54].	   Increased	   Ca2+	   -­‐Calmodulin	   and	   calmodulin	  
kinase	   II	   (CaMKII)	   activity,	   both	   common	   features	   of	   myocardial	  
remodelling	   in	   HF,	   have	   been	   shown	   to	   increase	   INaL.	   Recent	   evidence	  
identified	   CaMKII-­‐mediated	   phosphorylation	   of	   cardiac	   Na+	   channels	   at	  
multiple	   sites	   is	   the	   main	   regulator	   of	   Na+	   channel	   inactivation.	   INaL	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enhancement	   is	   associated	   with	   prolonged	   repolarisation	   causing	   a	  
remarkable	  increase	  in	  action	  potential	  duration	  	  [55,	  56].	  Atrial	  potential	  
prolongation	   leads	   to	   reduced	   repolarisation	   reserve	   and	   therefore	  
increased	   incidence	   of	   early	   afterdepolarizations	   (EADs,	   i.e.	   premature	  
depolarizations	  occurring	  during	  the	  plateau	  phase)	  and	  potentially	   fatal	  
arrhythmias	   	   [57].	  All	   these	  conditions	  are	  all	  characterized	  by	   increased	  
susceptibility	   to	   perturbations	   of	   repolarization	   (e.g.	   drugs	   blocking	   K+	  
currents	   or	   electrolyte	   imbalances)	   and	   overall	   increased	   risk	   of	  
arrhythmias.	  	  	  
	  
1.2.5	   Coronary	  microvascular	  dysfunction	  	  
By	  definition,	  cardiomyopathies	  are	  characterized	  by	  the	  absence	  of	  
acquired	  or	  congenital	  coronary	  artery	  disease	  at	  the	  epicardial	  level.	  Yet,	  
a	  quota	  of	  myocardial	   ischemia	  is	  virtually	  always	  present.	  This	   is	  due	  to	  
impairment	   of	   flow	   reserve	   at	   the	   microvascular	   level	   –	   a	   crucial	  
determinant	  of	  myocardial	  perfusion.	  Coronary	  microvascular	  dysfunction	  
has	   been	   demonstrated	   in	   diseases	   ranging	   from	   HCM,	   DCM,	   ARVC	   to	  
Anderson	   Fabry	   disease	   	   	   	   	   [58-­‐61].	   In	   most	   studies,	   impairment	   of	  
coronary	   reserve	   at	   this	   level	   has	   been	   shown	   to	   have	   profound	  
prognostic	   implications	   	   [62].	   Therefore,	   whatever	   the	   mechanism(s)	  
leading	  to	  microvascular	  dysfunction,	  the	  latter	  tends	  to	  take	  center	  stage	  
and	   determine	   disease	   progression	   and	   outcome	   when	   severe,	  
representing	   an	   important	   (and	   unfortunately	   yet	   unattainable)	  
therapeutic	   target.	   Mechanisms	   may	   be	   several:	   the	   most	   common	   is	  
non-­‐specific,	   represented	   by	   extravascular	   compression	   of	   the	   small	  
coronary	   vessels	   due	   to	   increased	   LV	   wall	   tension	   and	   fibrosis	   	   [63].	  
However,	   disease-­‐specific	   mechanisms	   exist,	   such	   as	   endothelial	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infiltration	  in	  storage	  disease	  	  (most	  notably	  Anderson-­‐Fabry	  disease)	  and	  
microvascular	  remodeling	  in	  HCM.	  	  
In	   HCM	   patients,	   microvascular	   remodeling	   is	   a	   striking	   and	  
consistent	  feature	  which	  occurs	  independent	  of	  hypertrophy,	  appears	  to	  
be	   genetically	   regulated	   [64],	   and	   may	   initiate	   as	   early	   as	   during	  
development	   [65].	   Abnormalities	   include	   marked	   thickening	   of	   the	  
intramural	  coronary	  arteriole	  wall,	  due	  to	  smooth	  muscle	  hyperplasia	  and	  
an	   abundance	   of	   disorganized	   elastic	   fibres,	   causing	   deformation	   and	  
irregular	  narrowing	  of	  the	  vessel	  lumen:	  as	  a	  consequence,	  their	  capacity	  
to	   vasodilate	   in	   response	   to	   physiological	   stimuli	   is	   markedly	   impaired.	  
Other	  factors	  contributing	  to	  microvascular	  dysfunction,	  such	  as	  disarray,	  
reduced	  capillary	  density	  and	  increased	  extravascular	  compressive	  forces,	  
are	  probably	  active	  in	  the	  most	  hypertrophied	  regions	  of	  the	  myocardium.	  	  
	  
1.2.6	   Fibrosis	  	  
Marked	   increase	   in	   the	   extracellular	   matrix	   is	   another	   common	  
theme	  in	  cardiomyopathy.	  Collagen	  synthesis	  may	  be	  primarily	  triggered	  
by	   altered	   fibroblast	   function	   (eg	   due	   to	   paracrine	   or	   neuroendocrine	  
influences)	  or	  as	  a	  reparative	  phenomenon	  following	  myocyte	  loss	  	  [66].	  	  	  	  
Primary	   (i.e.	   non	   ischemia-­‐mediated)	   activation	   of	   profibrotic	  
pathways	   is	   a	   consistent	   finding	   in	   patients	  with	   cardiomyopathies,	   and	  
has	   been	   demonstrated	   even	   in	   the	   pre-­‐clinical	   phase	   	   [67].	   These	  
pathways	   are	   associated	   with	   variable	   levels	   of	   interstitial	   fibrosis,	   the	  
clinical	   relevance	   of	   which	   remains	   uncertain.	   Of	   note,	   biomarkers	   of	  
collagen	   synthesis	   and	   degradation	   reflect	   collagen	   metabolism	   and	  
correlate	   with	   adverse	   outcomes	   in	   hypertension,	   heart	   failure,	   and	  
myocardial	   infarction.	   In	   HCM,	   studies	   of	   the	   links	   relating	   sarcomere	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protein	  mutations	   to	   the	  mechanisms	   that	   regulate	  vascular	   remodeling	  
and	  fibrosis	  are	  likely	  a	  key	  to	  our	  understanding	  of	  disease	  progression.	  
Recent	   studies	   have	   suggested	   that	   some	   phenotypic	   expressions	  
correlate	   more	   with	   altered	   function	   of	   fibroblasts	   than	   with	   myocyte-­‐
related	   pathology.	   Animal	   models	   of	   HCM	   that	   recapitulate	   human	  
disease	   have	   recently	   shed	   light	   on	   the	   earliest	   cellular	   and	   molecular	  
responses	   to	   sarcomere-­‐gene	   mutations	   [68].	   Cardiac	   transcriptional	  
profiling	   in	   young	   mice	   in	   which	   hypertrophy	   has	   not	   yet	   developed	  
shows	  activation	  of	  pathways	  involved	  in	  fibrosis	  and	  collagen	  deposition.	  
These	  studies	   indicate	  that	  a	  profibrotic	  milieu	   is	  present	  early	   in	  hearts	  
with	  HCM	  even	  when	  cardiac	  histologic	  findings	  are	  normal.	  	  
Replacement	   fibrosis	   is	   discrete,	   rather	   than	   interstitial,	   may	   be	  
transmural	   and	   occupy	   significant	   proportions	   of	   the	   left	   and/or	   right	  
ventricle,	  can	  be	  visualized	  in	  vivo	  as	  late	  gadolinium	  enhancement	  (LGE)	  
by	  CMR,	  and	  is	  generally	  associated	  with	  systolic	  dysfunction	  	  	  	  	  	  	  	  	  	  [69-­‐76].	  
LGE	   is	   believed	   to	   largely	   reflect	   a	   reparative	   process	   following	  
microvascular	  ischemia-­‐mediated	  damage	  –	  i.e.	  a	  scar	  [77].	  	  
The	   deposition	   of	   LGE	   varies	   according	   to	   the	   specific	   disease.	   In	  
HCM,	   areas	   of	   LGE	   have	   typical	   mid-­‐wall	   localization	   sparing	   the	  
subendocardial	   region	   [70-­‐76].	   CMR	   late	   gadolinium	   enhancement	   is	  
present	  in	  about	  two-­‐thirds	  of	  HCM	  patients,	  varying	  from	  very	  limited	  to	  
large,	  confluent,	   infarct-­‐like	  patches	  occupying	  significant	  proportions	  of	  
the	   LV	   [70,	   74].	   LGE	   localizes	   preferentially	   to	   the	   most	   hypertrophied	  
regions	  of	  the	  ventricle,	  often	  represented	  by	  the	  basal	  and	  mid-­‐septum,	  
and	  are	  more	  often	  found	  in	  patients	  with	  diffuse	  and	  severe	  hypertrophy.	  
Conversely,	  LGE	  is	  often	  absent	  in	  patients	  with	  mild	  HCM	  phenotype	  and	  
limited	   extension	   of	   hypertrophy	   [70,71].	   LGE	   is	   inversely	   related	   to	   LV	  
systolic	   function	   in	   HCM	   patients,	   and	   that	   those	   individuals	   who	   have	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reached	   the	   end-­‐stage	   phase	   of	   the	   disease,	   characterized	   by	   overt	  
systolic	   dysfunction	   and	   LV	   remodelling	   with	   progressive	   wall	   thinning,	  
constantly	   exhibit	   large	   and	   often	   transmural	   areas	   of	   LGE,	   which	  may	  
occupy	  as	  much	  as	  50%	  of	  the	  whole	  ventricular	  mass	  	  [78].	  Furthermore,	  
preliminary	   evidence	   points	   to	   LGE	   areas	   as	   a	   potential	   substrate	   of	  
ventricular	  arrhythmias	  [69,	  72].	  	  
In	   ARVC	   patients,	   phenotype,	   although	   genetically	   determined,	  
develops	  postnatally	  and	  is	  progressive	  with	  age,	  initiated	  by	  necrotic	  cell	  
death,	   which	   subsequently	   triggers	   an	   inflammatory	   response	   and	  
massive	   calcification	   within	   the	   myocardium,	   followed	   later	   by	   injury	  
repair	  with	  fibrous	  tissue	  replacement.	  In	  a	  Desmoglein	  2	  mutant	  mouse	  
model,	  necrosis	  always	  preceded	  other	  pathological	  signs	  of	  disease,	  such	  
as	   inflammation	   and	   calcification,	   and	   later	   on,	   fibrosis,	   ventricular	  
dilation,	   and	   aneurysm	   formation.	   Furthermore,	   myocyte	   necrosis	  
originated	   in	   the	   subepicardial	   myocardium,	   followed	   by	   a	   wave-­‐front	  
extension	  toward	  the	  endocardium	  [79].	  This	  wave-­‐front	  phenomenon	  of	  
myocardial	   atrophy	   is	   well	   documented	   in	   human	   ARVC,	   both	   by	  
histopathologic	   examinations	   and	   cardiac	   magnetic	   resonance	   studies	  	  
[80,	  81].	  
Both	   reactive	   (interstitial	   and	   perivascular)	   and	   reparative	  
(replacement)	  myocardial	  fibrosis	  (MF)	  are	  hallmarks	  of	  DCM	  	  	  	  [82-­‐84].	  In	  
vivo	   assessment	   of	   myocardial	   fibrosis	   by	   CMR	   in	   DCM	   patients	   have	  
shown	   a	   prevalence	   of	   significant	   LGE	   in	   almost	   50%,	   with	   mid-­‐wall	  
distribution	  and	  typical	  sparing	  of	  the	  subendocardium	  –	  a	  useful	  marker	  
to	   rule	   out	   ischemic	   dilated	   cardiomyopathy.	   Fibrosis	   is	   a	   predictor	   of	  
outcome	  and	  reverse	  remodeling	  following	  HF	  therapy;	  of	  note,	   it	   is	   less	  
prevalent	  in	  DCM	  caused	  by	  myocarditis,	  in	  which	  LV	  dysfunction	  may	  be	  
reversible,	  compared	  to	  genetic	  DCM	  [85].	  	  




1.2.7	   Developmental	  aspects	  
At	   birth,	   patients	   with	   genetic	   cardiomyopathies	   generally	   exhibit	  
normal	   hearts,	   and	   the	   full-­‐fledged	   phenotype	   may	   develop	   at	  
adolescence	   or	   during	   adult	   life;	   pediatric	   onset	   is	   rare	   but	   possible.	  	  
When	  the	  phenotype	  develops,	  a	  number	  of	  tissues	  and	  cell	  types	  that	  do	  
not	   express	   the	   mutated	   gene	   are	   found	   to	   actively	   participate	   in	   the	  
disease	  process,	   in	  ways	   that	  are	  hard	   to	  explain	   simply	  on	   the	  basis	  of	  
secondary,	  bystander,	  involvement.	  To	  date,	  the	  link	  between	  the	  genetic	  
defect	   such	  “extended”	  phenotype	   remains	  elusive.	  Among	   the	  possible	  
explanation,	   the	  hypothesis	  of	  cardiomyopathies	  as	  cell	   lineage	  diseases	  
has	  emerged,	  by	  which	  pre-­‐natal	  mechanisms	  directly	  linked	  to	  the	  causal	  
gene	   defect	   acts	   upon	   multipotent	   progenitors	   to	   influence	   their	  
commitment	  and	  ultimate	  development	  [65].	  	  
For	  example,	  theories	  explaining	  the	  development	  of	  hypertrophy	  in	  
HCM	   patients	   fail	   to	   address	   aspects	   of	   HCM	   as	   diverse	   as	   interstitial	  
fibrosis,	   microvascular	   remodeling	   and	   mitral	   valve.	   Specific	   features,	  
such	   as	   direct	   papillary	   insertion	   into	   the	   mitral	   leaflet	   or	   myocardial	  
bridging,	   clearly	   suggest	   a	   developmental	   defect	   [86].	   Our	   group	   has	  
proposed	  [65]	  that	  a	  common	  lineage	  ancestry	  for	  these	  extramyocardial	  
phenotypes	   can	   be	   traced	   back	   to	   the	   proepicardial	   organ,	   originating	  
from	   the	   posterior	   component	   of	   the	   secondary	   heart	   field	   [87].	   Early	  
during	  development,	   the	  migration	  of	  proepicardial	  cells	  over	   the	  naked	  
heart	   tube	   originates	   the	   epicardium.	   Following	   a	   process	   called	  
epithelial-­‐mesenchymal	   transformation,	   apparently	   pluripotent	  
epicardium-­‐derived	  cells	   (EPDCs)	  subsequently	  migrate	  diffusely	   into	  the	  
myocardium	   and	   differentiate	   into	   diverse	   cell	   types	   which	   give	   rise	   to	  
cardiac	   scaffolding	  as	   interstitial	   fibroblasts,	   to	   the	  coronary	  vasculature	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as	   smooth	   muscle	   cells	   and	   adventitial	   fibroblasts,	   and	   to	   the	   atrio-­‐
ventricular	   cushion	   tissue	   as	  mesenchymal	   cells	   [87].	   At	   the	   time	  when	  
EPDC	   migration	   occurs	   from	   the	   epicardium	   into	   the	   myocardium,	   the	  
heart	   has	   already	   begun	   to	   contract,	   and	   most	   known	   HCM-­‐causing	  
mutations,	   such	   as	   those	   involving	   the	   beta-­‐myosin	   heavy	   chain	   and	  
myosin-­‐binding	  protein	  C	  genes,	  are	  already	  expressed	   in	  the	  embryonic	  
heart	  [87,	  88].	  Therefore,	  it	  is	  tempting	  to	  speculate	  that	  an	  interference	  
with	   the	   EPDC	   migration	   and	   differentiation	   processes,	   by	   a	   putative	  
mechanism	   of	   mechanotransduction	   [89],	   may	   account	   for	   features	   as	  
diverse	   as	   myocardial	   disarray,	   interstitial	   fibrosis,	   mitral	   valve	  
abnormalities	   and	   microvascular	   remodeling	   [65].	   Another	   explanation	  
for	  why	  a	  mutation	  in	  sarcomeric	  proteins	  can	  affect	  valve	  development	  is	  
that	  during	  development,	  EPDCs—rather	  than	  becoming	  hypertrophic	  like	  
other	  cardiomyocytes—differentiate	  or	  revert	  into	  fibroblastic-­‐like	  cells.	  If	  
this	   is	  true,	  one	  would	  expect	   increased	  levels	  of	  periostin	  production	  in	  
hypertrophic	   hearts	   since	   the	   hallmark	   of	   fibroblastic	   differentiation	   is	  
expression	   of	   periostin.	   Consistent	   with	   this	   hypothesis,	   markedly	  
elevated	  levels	  of	  periostin	  are	  indeed	  expressed	  in	  HCM	  mice	  [90].	  	  
Similar	   hypotheses	  may	   explain	   the	   cellular	   origin	   of	   adipocytes	   in	  
ARVC,	  which	   represents	   an	  enigma	   [91].	   In	   the	  heart,	   the	  only	   cell	   type	  
known	  to	  express	  desmosomal	  proteins	   is	   the	  cardiomyocyte,	  which	  are	  
terminally	   differentiated	   in	   the	   adult	   and	   hence	   not	   candidates	   to	  
dedifferentiate	  to	  adipocytes.	  However,	  lineage	  tracing	  experiments	  have	  
shown	  showed	  that	  adipocytes	  in	  ARVC	  originate	  from	  second	  heart	  field	  
progenitor	   cells	   that	  preferentially	  differentiate	   into	  adipocytes	  because	  
of	  suppressed	  canonical	  Wnt	  signaling.	  Indeed,	  Wnt/β-­‐catenin	  signaling	  is	  
an	   important	   switch	   regulator	  of	  myogenesis	   versus	   adipogenesis	   and	  a	  
differentiation	  of	  cardiac	  progenitor	  cells.	  These	  findings	  may	  also	  explain	  
1.	  Introduction:	  tales	  of	  the	  unexpected	  
34	  
	  
the	  predominant	   involvement	  of	   the	   right	  ventricle	   in	  ARVC,	  as	   that	   the	  
second	   heart	   field	   progenitors	   give	   rise	   to	   the	   right	   ventricle	   and	   its	  
outflow	  tracts	  through	  mechanisms	  governed	  by	  canonical	  Wnt	  signaling.	  
Further	   understanding	   of	   the	   effects	   of	   cardiomyopathy-­‐causing	  
mutations	  during	  development,	  and	   their	  protean	   implication	  on	  clinical	  
phenotype,	   may	   provide	   important	   clues	   on	   the	   essence	   of	   genetic	  
cardiac	  disease.	  These	  are	  difficult	   studies	   to	  perform,	  and	   require	  hard	  
multidisciplinary	  work.	  However,	   the	   rewards	  may	   include	   a	   completely	  
new	  way	  of	  conceiving	  the	  spectrum	  of	  these	  conditions,	  as	  well	  as	  novel	  
therapeutic	  targets.	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1.3	   Making	   sense	  of	   diversity:	   finding	   common	  answers	  
in	  clinical	  practice.	  
	  
Imagining	  a	  disease	  as	  a	  fruit	  or	  a	  planet,	  there	  are	  several	  levels	  at	  
which	   one	   can	   intervene	   with	   any	   therapeutic	   approach.	   The	   first	   and	  
most	  obvious	  is	  to	  simply	  scratch	  the	  surface	  and	  control	  symptoms.	  This	  
objective	  can	  be	  achieved	  in	  most	  cardiac	  patients:	  however,	  it	  is	  the	  very	  
least	  we	  can	  do.	  The	  second	  step	  is	  to	  interfere	  and	  possibly	  halt	  disease	  
progression,	   thus	   preventing	   its	   consequences	   on	   outcome:	   this	   can	   be	  
done	   in	   several	   cardiac	   conditions,	   but	   is	   definitely	   harder	   to	   achieve	  	  	  
[92-­‐93].	   Third,	   we	   can	   try	   to	   prevent	   the	   development	   of	   full-­‐blown	  
disease	   in	   patients	   who	   are	   predisposed	   due	   to	   acquired	   risk	   factors	  
and/or	  genetic	  substrate	  [94].	  And	  fourth,	  we	  can	  address	  the	  core	  of	  the	  
problem	  by	  acting	  directly	  on	  the	  etiology,	  removing	  the	  actual	  cause	  and	  
ultimately	  cure	  the	  patient	  [95].	  	  Despite	  extraordinary	  progress	  over	  the	  
last	   decades,	   these	   last	   two	   steps	   have	   hardly	   ever	   been	   achieved	   in	  
cardiovascular	  medicine.	  As	  a	  consequence,	  it	  is	  important	  to	  realize	  that	  
our	   practice	   is	   based	   on	   highly	   sophisticated	   palliation.	   What	   this	  
approach	  usually	  does	  is	  change	  a	  disease	  into	  a	  milder	  one.	  For	  example	  
septal	  myectomy	  turns	  obstructive	  into	  non-­‐obstructive	  HCM,	  and	  the	  ICD	  
can	  prevent	  malignant	  arrhythmias	  in	  ARVC	  or	  DCM,	  all	  highly	  significant	  
benefits	   for	   the	  patients	   	   [96,	   97].	   Therefore,	   this	   kind	  of	   very	   effective	  
palliation	  is	  something	  we	  should	  definitely	  keep	  on	  doing,	  and	  improving,	  
until	  a	  cure	  becomes	  available.	  However,	  all	  efforts	  should	  be	  directed	  at	  
improving	   the	   state	   of	   things	   by	   accumulating	   new	   evidence	   and	  
knowledge	  [98].	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Despite	  decades	  of	  increasing	  attention	  and	  research	  efforts	  by	  the	  
scientific	   community,	   treatment	   strategies	   for	   cardiomyopathies	   remain	  
largely	  based	  on	  a	  small	  number	  of	  clinical	   studies,	  or	  empirically	  based	  
on	  personal	  experience	  or	  extrapolation	  from	  other	  cardiac	  conditions.	  As	  
stated	  in	  the	  recent	  Report	  of	  the	  Working	  Group	  of	  the	  National	  Heart,	  
Lung,	   and	   Blood	   Institute	   on	   Research	   Priorities	   in	   Hypertrophic	  
Cardiomyopathy	  [98],	  “nearly	  50	  years	  after	  the	  identification	  of	  HCM	  as	  
an	   autosomal	   dominant	   disease,	   and	   20	   years	   after	   its	   linkage	   to	  
sarcomeric	   protein	   mutations,	   we	   still	   do	   not	   understand	   the	   most	  
proximal	   mechanism(s)	   that	   initiates	   the	   disorder”;	   and	   “treatment	  
recommendations	   in	   HCM	   are	   based	   on	   observational	   series	   without	  
prospective	   randomized	   controls.	   While	   clinical	   usage	   provides	   support	  
that	   various	  pharmacologic	   agents	   reduce	  HCM	   symptoms,	   no	   evidence	  
has	  demonstrated	  that	  they	  alter	  disease	  progression	  or	  outcomes.”	  In	  a	  
recent	   review	   of	   original	   articles,	   reviews	   and	   editorials	   addressing	   any	  
pharmacological	   agent	   ever	   used	   in	  HCM	   cohorts,	   only	   45	   studies	  were	  
identified	  over	   the	   last	   sixty	   years	   (i.e.	   less	   than	  1	  per	   year),	   enrolling	  a	  
total	   of	   2,121	   HCM	   patients	   [95].	   Of	   these,	   only	   5	   were	   randomized,	  
double	  blind	  placebo-­‐controlled	   trials.	   Remarkably,	   a	   comparison	  of	   the	  
period	  1991-­‐2011	  vs.	  1971-­‐1990	  demonstrated	  no	  increase	  in	  the	  number	  
of	  studies,	  and	  only	  a	  modest	  increase	  in	  the	  number	  of	  patients	  enrolled	  
(627	  vs.	  1,473,	  patients	  respectively).	  	  
Several	   reasons	   -­‐	   some	   obvious,	   other	   less	   so	   -­‐	   stand	   behind	   this	  
state	   of	   things.	   The	   first	   lies	   with	   the	   practical	   challenges	   inherent	   in	  
designing	  trials	  with	  cardiomyopathy	  patients.	  The	  epidemiology	  of	  these	  
conditions	   is	   complex	   and	   only	   partially	   known,	   due	   to	   issues	   such	   as	  
scarce	   awareness,	   incomplete	   penetrance	   and	   prevalence	   of	   subclinical	  
disease	   [67].	  Despite	  not	  being	   rare,	  cardiomyopathies	  are	  uncommonly	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encountered	  and	  possibly	  neglected	  at	  community-­‐based	  cardiac	  centers	  
and	   outpatient	   clinics.	   Furthermore,	   even	   when	   overt	   and	   correctly	  
diagnosed,	  their	  clinical	  spectrum	  is	  highly	  heterogeneous,	  encompassing	  
different	  stages	  that	  may	  not	  be	  directly	  comparable.	  A	  preventive	  trial	  in	  
genotype-­‐positive	  /	  phenotype-­‐negative	  individuals	  will	  necessarily	  enroll	  
subsets	   that	   are	   different	   from	   patients	   with	   end-­‐stage	   disease.	   Each	  
research	   question	   should	   be	   addressed	   by	   targeting	   the	   appropriate	  
patient	   subgroups,	   with	   imaginable	   problems	   in	   achieving	   the	   desired	  
yield	  in	  any	  given	  cohort	  [98].	  
As	  highlighted	  in	  the	  previous	  section,	  several	  targets	  for	  treatment	  
have	  been	  identified,	  some	  of	  which	  overlap	  with	  other	  cardiac	  diseases	  
and	  with	  heart	  failure	  at	  large.	  	  
	  
Figure	  1.3-­‐1:	  Therapeutic	  targets	  and	  goals	  in	  cardiomyopathies	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For	   example,	  progressive	   interstitial	   cardiac	   fibrosis,	   resulting	   from	  
non–myocyte	   (e.g.,	   fibroblast)-­‐mediated	   activation	   of	   transforming	  
growth	  factorβ	  signaling,	  is	  a	  common	  feature	  of	  most	  cardiomyopathies	  
[4].	  The	  finding	  that	  preemptive	  angiotensin	  II	  type	  1–receptor	  inhibition	  
prevented	  myocardial	   fibrosis	   in	   a	  mouse	  model	   of	   cardiomyopathy,	   as	  
well	   as	   encouraging	   results	   from	  a	   small	   clinical	   study,	   supports	   further	  
investigation	  of	  this	  approach	  [28].	  
Furthermore,	   interventions	   aimed	   at	   normalizing	   energy	  
homeostasis	  represent	  a	  viable	  approach,	  as	  shown	  by	  a	  recent	  study	  on	  
perhexiline,	  a	  metabolic	  modulator	  which	  inhibits	  the	  metabolism	  of	  free	  
fatty	  acids	  and	  enhances	  carbohydrate	  utilization	  by	   the	  cardiomyocyte.	  
In	   a	   randomized,	   double-­‐blind	   placebo-­‐controlled	   trial,	   perhexiline	   has	  
recently	   shown	   the	   capacity	   to	   improve	   the	   energetic	   profile	   of	   the	   LV,	  
resulting	   in	   improved	   diastolic	   function	   and	   exercise	   capacity	   in	   HCM	  
patients	  [99].	  HCM	  cardiomyocytes	  exhibit	  well-­‐established	  abnormalities	  
in	   intracellular	   calcium	   handling,	   contributing	   to	   excessive	   energy	  
expenditure	   and	   enhanced	   arrhythmogenesis,	   that	   are	   largelydue	   to	  
enhanced	   membrane	   late	   sodium	   current	   [100].	   Such	   defect	   may	   be	  
selectively	  and	  dramatically	  reversed	  in	  vitro	  by	  ranolazine.	  Following	  the	  
demonstration	   of	   its	   beneficial	   effects	   on	   HCM	   cardiomyocytes,	   a	  
multicenter,	   double	   blind,	   placebo-­‐controlled	   pilot	   study	   is	   currently	  
underway	   in	   Europe,	   to	   test	   the	   efficacy	   of	   ranolazine	   on	   exercise	  
tolerance	  and	  diastolic	   function	   in	  symptomatic	  HCM	  patients	   (RESTYLE-­‐
HCM;	   EUDRA-­‐CT	   2011-­‐004507-­‐20).	   Besides	   the	   specific	   merits	   of	  
ranolazine,	   similar	   examples	   of	   translational	   approach	   identify	   a	  
fundamental	   pre-­‐requisite	   for	   the	   identification	   of	   novel,	   potentially	  
effective	  agents,	  based	  on	  thorough	   investigation	  of	   the	  molecular	  basis	  
of	  these	  diseases.	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In	   the	   future,	  a	  more	   specific	  approach	  may	  be	   tailored	   to	   specific	  
mutations	  or	   groups	  of	  mutations	  associated	  with	   cardiomyopathies,	  by	  
screening	  large	  panels	  of	  candidate	  molecules	  in	  assays	  based	  on	  induced	  
pluripotent	   stem	   cells	   isolated	   from	   human	   fibroblasts	   [101].	   As	   shown	  
recently,	   the	   possibility	   of	   modulating	   the	   activity	   of	   sarcomere	  
contractile	   proteins,	   such	   as	   beta-­‐myosin,	   is	   beginning	   to	   surface,	   with	  
huge	  potential	  implications	  for	  treatment	  of	  DCM,	  HCM	  and	  heart	  failure	  
in	   general	   [102].	   Finally,	   during	   heart	   development,	   immature	  
cardiomyocytes	  proliferate	  actively	  to	  accommodate	  increasing	  heart	  size	  
and	   function	   [103];	   however,	   this	   proliferation	   is	   abruptly	   abrogated	  
shortly	  after	  birth,	   leaving	  the	  heart	  with	  a	  limited	  regenerative	  capacity	  
insufficient	  to	  replace	  substantial	  amounts	  of	  tissue	   lost	  after	   injury.	  For	  
conditions	   characterized	   by	   loss	   of	   viable	   myocardial	   tissue	   and	  
dysfunction,	   such	   as	   DCM	   and	   ARVC,	   an	   promising	   approach	   is	  
constituted	   by	   the	   possibility	   of	   reactivating	   the	   dormant	   proliferative	  
capacity	  of	  adult	  cardiomyocytes	  as	  a	  direct	  effect	  of	  miRNA	  delivery.	  In	  a	  
recent	   study,	   selected	   miRNAs	   showed	   the	   ability	   of	   selectively	   induce	  
cardiomyocyte	   proliferation	   in	   vitro	   and	   in	   vivo.	   miRNA	   delivery	   to	   the	  
infarcted	  heart	  resulted	   in	  structural	  and	  functional	  recovery.	  Therefore,	  
the	   broader	   action	   of	  miRNAs	   impacting	  multiple	   pathways	   opens	   up	   a	  
new	   translational	   perspective	   for	   the	   treatment	   of	   complex	   cardiac	  
disease	   as	   a	   stand-­‐alone	   therapy	   or	   in	   combination	   with	   other	  
regenerative	  resources.	  Likewise,	  control	  of	  gene	  transcription	  by	  specific	  
interaction	   with	   histone	   acetylation	   and	   deacetylation	   (by	   the	  
antagonistic	   families	   of	   histone	   acetyltransferases	   and	   histone	  
deacetylases)	   may	   represent	   a	   viable	   therapeutic	   pathway	   in	   genetic	  
heart	   disease,	   with	   targets	   ranging	   from	  modulation	   of	   hypertrophy	   to	  
cardiac	  regeneration	  [104].	  	  




Overall,	   these	   broad	   concepts	   provide	   a	   broad	   intellectual	  
framework	  supporting	  the	   idea	  of	  a	  common	  pathophysiologic	  “core”	  of	  
primary	  heart	  muscle	  disease,	   representing	  a	  unitary	   target	   for	   research	  
efforts	  in	  the	  field.	  Although	  the	  final	  application	  of	  future	  therapies	  will	  
be	  necessarily	   individualized	   (i.e.	  both	  disease-­‐	  and	  patient-­‐specific),	   the	  
beginning	   of	   this	   therapeutic	   revolution	   will	   be	   based	   on	   the	  
comprehensive	  understanding	  of	  cardiomyopathies	  as	  a	  whole.	  Similar	  to	  
what	  is	  happening	  in	  cancer	  or	  autoimmune	  diseases,	  it	  will	  be	  impossible	  
to	  cure	  a	  single	  entity	  without	  being	  near	  to	  curing	  the	  rest.	  Rather	  than	  
subdividing	  the	  field	  in	  water-­‐proof	  niches	  with	  little	  communication,	  the	  
approach	   to	   cardiomyopathies	   should	   constantly	   strive	   to	   pursue	   the	  
inter-­‐disciplinary	  cross-­‐fertilization.	  It	  is	  hoped	  that	  the	  present	  work	  may	  
contribute	  to	  this	  novel	  perspective.	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1.4	   Aim	  of	  the	  thesis	  and	  project	  design.	  
	  
The	   present	   thesis	   reflects	   several	   aspects	   of	   my	   work	   at	   the	  
Florence	   Referral	   Center	   for	   Cardiomyopathy	   and	   Careggi	   University	  
Hospital	   during	   the	   last	   3	   years.	   The	   leading	   theme	   is	   the	   effort	   to	  
embrace	   the	   complexities	   of	   cardiomyopathies	   using	   a	   translational	  
approach	  ranging	  from	  clinical	  to	  imaging,	  to	  genetics,	  to	  basic	  science.	  	  
Section	   2	   focuses	   on	   genotype-­‐phenotype	   correlations	   in	   two	  
specific	   disease	   models	   (thin	   filament-­‐associated	   HCM	   and	   Anderson	  
Fabry	   disease)	   and	   the	   impact	   of	   next	   generation	   sequencing	   on	   the	  
diagnosis	  of	  clinically	  challenging	  cardiomyopathies.	  Section	  3	  deals	  with	  
the	   hypothesis	   that	   environmental	   modifiers	   may	   exert	   a	   significant	  
impact	  on	  phenotype	  and	  clinical	  course,	  by	  addressing	  one	  of	  the	  most	  
prevalent	  cardiovascular	   risk	   factor	   in	   the	  western	  world,	   i.e.	  obesity,	   in	  
HCM	  patients	  undergoing	  cardiac	  magnetic	  resonance	  imaging.	  Section	  4	  
addresses	   clinical	  markers	   of	   risk	   and	  predictors	   of	   outcome	   in	   patients	  
with	   HCM	   (by	   evaluating	   the	   value	   of	   NT-­‐pro	   BNP	   and	   late	   gadolinium	  
enhancement	   as	   a	   clinical	   barometers	   of	   disease	   progression	   and	  
arrhythmic	  risk),	  DCM	  (assessing	  the	  impact	  of	  advances	  in	  management	  
on	  outcome),	  and	  an	  acquired	  model	  of	  myocardial	  disease	  involving	  cell-­‐
mediated	  immunity	  –	  Chagas	  cardiomyopathy.	  Section	  5	  illustrates	  novel	  
therapeutic	  approaches	  that	  are	  being	  developed	  for	  patients	  with	  HCM	  
and	   Anderson-­‐Fabry	   disease,	   and	   a	   critical	   reappraisal	   of	   a	   well-­‐
established	  –	  but	  not	  perfect	  –	  preventive	  option	  such	  as	  the	  implantable	  
cardioverter	  defibrillator.	  	  Finally,	  in	  my	  conclusive	  remarks,	  I	  will	  outline	  
work	   that	   is	   presently	   ongoing	   and	   future	   directions	   for	   research	   to	   be	  
pursued	  in	  Florence.	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is not so much to obtain new facts,  
as to discover new ways  
of thinking about them” 
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Genetics	   is	   a	   new	   science.	  It	   is	   little	   more	   than	   a	   century	   since	  
Mendel's	  laws	  were	  rediscovered	  in	  1900,	  and	  less	  than	  60	  years	  since	  the	  
structure	   of	   DNA	  was	   discovered	   in	   1953.	   Human	   and	  medical	   genetics	  
were	  late	  developers:	  they	  started	  to	  slowly	  develop	  during	  the	  first	  half	  
of	  the	  20th	  century,	  then	  saw	  an	  increasingly	  rapid	  rise	  and	  continues	  in	  
the	   21st	   century.	   Thanks	   to	   the	   outstanding	   efforts	   of	   Victor	   Almon	  
McKusick,	   now	   regarded	   as	   the	   “father	   of	   medical	   genetics”,	   in	   the	  
second	   half	   of	   the	   20th	   century	   genetics	  met	  medicine.	   Since	   then,	   the	  
Holy	  Grail	   in	  medical	   genetic	   has	  been	   the	   ability	   to	  deduce	   the	   clinical	  
phenotype	   of	   an	   individual	   from	   his	   genotype.	   It	   was	   once	   naively	  
assumed	   that,	   at	   least	   for	   ‘‘monogenic’’	  disorders,	   genotype–phenotype	  
relationships	  would	  be	  simple	  and	  straightforward	  to	  understand.	  This	  era	  
of	   substantial	   optimism	   conquered	   the	   whole	   word	   of	   medicine:	  
physicians	   and	   geneticists	   shared	   the	   unrealistic	   expectation	   that	  
molecular	   genetics	   would	   lead	   to	   a	   new	   paradigm	   in	   predicting	   the	  
outcome	  of	  patients.	  	  
What	   was	   initially	   thought	   to	   be	   one-­‐to-­‐one	   gene-­‐disease	   has	  
turned	  out	  to	  display	  important	  variability,	  dependent	  in	  large	  part	  on	  the	  
genetic	   and	   environmental	   backgrounds	   into	   which	   the	   genes	   express.	  
Therefore,	   the	   reality	   is	   that	   we	   cannot	   readily	   draw	   straight	   lines	   of	  
causation	  from	  known	  genotypes	  to	  specific	  clinical	  phenotypes	  [Fig	  2-­‐1].	  
Although	   the	   original	   goal	   to	   link	   genotype	   to	   phenotype	   remains,	   it	   is	  
now	  clear	  that	  the	  overall	  complexity	  of	  this	  relationship	  will	  require	  a	  far	  
more	   subtle	   understanding	   of	   both	   molecular	   mechanisms	   and	   clinical	  
correlates.	  Furthermore,	  there	  is	  an	  additional	  and	  perhaps	  central	   issue	  
that	   compromise	   our	   ability	   to	   match	   genotype	   to	   phenotype:	   the	  
progressive	  nature	  of	  the	  cardiac	  pathogenic	  process.	  Longitudinal	  studies	  
of	  patients	  with	  cardiomyopathies	  have	  documented	  the	  dynamic	  nature	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of	   the	  ventricular	   remodeling.	  Thus,	   it	   is	  apparent	   that	   focusing	  only	  on	  
the	  end	  phenotype	  as	  the	  supposed	  “link”	  to	  the	  molecular	  mechanism	  is	  
not	  only	  limiting	  but	  also	  likely	  to	  be	  misleading.	  
	  
	  
Figure	  2-­‐1:	  Genotype-­‐phenotype	  correlations	  
The	   connections	   between	   phenotype	   and	   genotype	   are	   complex	   and	  
quite	  hard	  to	  understand.	  Even	  in	  monogenic	  disorders,	  the	  same	  genetic	  
variant	  can	  lead	  to	  different	  clinical	  pictures.	  The	  expression	  of	  phenotype	  
may	  be	  modulated	  by	  a	  variety	  of	  genetic	  and	  non-­‐genetic	  factors.	  Among	  
the	  former,	  the	  type	  of	  mutation,	  the	  phenomenon	  of	  allele	  dosage,	  the	  
presence	   of	   modifiers	   gene	   and	   epigenetics	   modifications	   are	   those	  
better	   known.	   Environmental	   factors	   are	   those	  who	   are	  modifiable	   and	  
can	  be	  have	  a	  vigorous	   influence	  on	  phenotypic	  expression	  (see	  chapter	  
3).	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2.1	   Into	   the	   myocardium:	   the	   distinct	   phenotypic	  
expression	   of	   thin	   filament	   mutations	   in	   hypertrophic	  
cardiomyopathy	  
	  
It	  was	  in	  a	  cold	  and	  rainy	  day	  of	  November	  that	  we	  first	  have	  the	  
idea	   of	   designing	   this	   study.	   At	   the	   end	   of	   a	   very	   busy	  morning	   in	   the	  
outpatient	  clinic,	  we	  were	  reviewing	  the	  most	  interesting	  cases	  of	  the	  day.	  
That	  morning	  we	  evaluated,	   totally	  by	   chance,	   three	  patients	  with	  HCM	  
due	   to	   mutations	   in	   the	   thin	   filament	   genes.	   We	   were	   discussing	   the	  
patients,	   their	   clinical	   history	   and	   disease	   progression.	   We	   were	   also	  
analyzing	   echo	   images,	   one	   after	   another,	   and	   in	   that	   moment	   we	  
realized	  how	  they	  were	  part	  of	  a	  distinct	  subgroup,	  if	  compared	  to	  other	  
patients	  with	  mutations	  in	  thick	  filament	  genes.	  	  
HCM	  is	  a	  disease	  of	  the	  sarcomere:	  mutations	  are	  very	  often	  found	  
in	   one	   of	   the	   two	   genes	   encoding	   for	   thick	   filament	   proteins	   (myosin	  
binding	  protein	  C	  -­‐MYPC3	  and	  myosin	  heavy	  chain	  -­‐	  MYH7)	  [Fig.	  2.1-­‐1]	  [1].	  
Mutations	   in	   the	   thin	   filament	   regulatory	   protein	   genes	   accounts	   for	   a	  
minority	   of	   molecular	   defect	   involved	   in	   HCM	   and	   includes	   cardiac	  
troponin	   T	   (TNNT2)	   and	   I	   (TNNI3),	   alpha-­‐tropomyosin	   (TPM1),	   cardiac	  
actin	   (ACTC)	  and,	   very	   rarely,	   troponin	  C	   [2].	   These	  mutations,	   although	  
rare,	  have	  always	  seduced	  physicians	  and	  geneticists	  involved	  in	  the	  field,	  
because	   of	   them	   ominous	   outcome	   and	   high	   prevalence	   of	   malignant	  
arrhythmias	  especially	  in	  the	  young.	  	  
Prior	  reports	  of	  patients	  with	  thin	  filament	  mutations	  described	  a	  
severe	   form	   of	   HCM	   characterized	   by	   early	   onset,	   mild	   degrees	   of	  
hypertrophy	  and	  high	  prevalence	  of	  juvenile	  sudden	  cardiac	  death	  	  	  	  	  [3-­‐6].	  
Despite	   the	   low	   statistic	   power	   of	   these	   studies,	   limited	   by	   sample	   size	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and	   a	   cross-­‐sectional	   design,	   such	   rumor	   spread	   quickly	   among	  
cardiologists,	   and	   these	   mutations	   are	   now	   known	   as	   “malignant	  
mutations”.	   However,	   recent	   reports	   have	   shown	   that	   the	   overall	  
spectrum	   of	   thin	   filament-­‐HCM	   is	   far	   more	   heterogeneous	   than	  
previously	  thought,	  extensively	  overlapping	  the	  more	  prevalent	  forms	  of	  
HCM	  associated	  with	  thick	  filament	  mutations	  [7].	  	  
	  
	  
Figure	  2.1-­‐1:	  	  The	  sarcomere	  
The	   upper	   panel	   shows	   a	   transmission	   electron	  micrograph	  
of	   a	   human	   cardiac	   sarcomere.	   The	   lower	   portion	   of	   the	  
figure	  shows	  a	  simplified	  illustration	  of	  the	  sarcomere.	  	  
	  
Two	   important	   questions	   arise	   from	   these	   considerations:	   is	   thin	  
filament	   HCM	   a	   distinct	   disease?	   How	   and	   why	   is	   thin	   filament	   HCM	  
different	  from	  the	  more	  common	  thick-­‐filament	  disease?	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Given	  the	  international	  network	  in	  which	  our	  center	  was	  involved,	  
we	  decided	  to	  design	  a	  multicenter	  study,	  in	  order	  to	  describe	  the	  clinical	  
features	   and	   outcome	   of	   a	   large	   cohort	   of	   patients	   with	   thin	   filament	  
HCM,	   compared	   to	   matched	   patients	   with	   pathogenic	   thick	   filament	  
mutations.	   The	   study	   cohort	   comprised	   84	   patients	   with	   a	   clinical	  
diagnosis	   of	   HCM	   associated	   with	   one	   or	   more	   thin	   filament	   gene	  
mutations	   (including	   cardiac	   troponin	   T	   (TNNT2)	   and	   I	   (TNNI3),	  
tropomyosin	   (TPM1)	   and	   cardiac	   actin	   (ACTC),	   while	   no	   troponin	   C	  
mutations	   were	   found),	   while	   157	   HCM	   patients	   with	   pathogenic	  
mutations	  in	  the	  thick	  filament	  genes	  (MYBPC3	  and	  MYH7)	  were	  used	  as	  
controls	   [Fig	   2.1-­‐1].	   Four	   referral	   centers	   for	   cardiomyopathies	   were	  
involved	   in	   the	   study:	   Careggi	   University	   Hospital	   in	   Florence,	   Italy;	  
Brigham	  and	  Women's	  Hospital	   in	  Boston;	   Stanford	  Medical	   Center	   and	  
University	  of	  Michigan	  Medical	  Center	  in	  Ann	  Arbor.	  	  
Patients	   underwent	   a	   thorough	   clinical	   and	   instrumental	  
evaluation,	  including	  clinical	  history,	  echocardiography,	  12-­‐lead	  basal	  and	  
24-­‐hours	   ambulatory	   ECG	   and	   cardiac	   magnetic	   resonance.	   They	   were	  
followed-­‐up	   at	   yearly	   intervals	   with	   review	   of	   history	   and	   symptoms,	  
physical	   examination,	   and	   echocardiographic	   examination,	   and	  
electrocardiography.	  24-­‐	  to	  48-­‐hour	  ambulatory	  ECG	  monitoring	  and	  CMR	  
were	  performed	  if	  clinically	  indicated.	  	  
The	   phenotype	   of	   patients	   with	   thin-­‐filament	   mutations	   slowly	  
started	   to	   reveal	   itself.	   Compared	   with	   patients	   with	   thick	   filament	  
disease,	   thin	   filament	   HCM	   seemed	   to	   represent	   a	   distinct	   and	   well-­‐
defined	   subset,	   in	   terms	   of	   cardiac	   morphology,	   systolic	   and	   diastolic	  
myocardial	  function	  and	  patterns	  of	  disease	  progression.	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2.1.1	   Cardiac	  morphology	  and	  arrhythmic	  burden	  
The	   “thin	   filament”	   heart	   appeared	   to	   be	   less	   prone	   to	   develop	  
severe	   hypertrophy.	   Mean	   maximal	   LV	   wall	   thickness	   values	   were	   on	  
average	   milder	   than	   that	   observed	   in	   the	   thick	   filament	   group.	  
Furthermore,	  the	  distribution	  of	  hypertrophy	  within	  the	  left	  ventricle	  was	  
atypical,	  with	  high	  prevalence	  of	  concentric	  and	  apical	  patterns	  whereas	  
thick	   filament	   HCM	   was	   almost	   uniformly	   (94%)	   manifest	   as	   classic	  
asymmetric	  LVH	  involving	  the	  basal	  septum	  and	  anterior	  wall	  [Figure	  2.1-­‐
2].	   The	   atypical	   distribution	   of	   hypertrophy,	   together	   with	   the	   mild	  
degree	  of	  hypertrophy,	  also	  accounted	  for	  the	   low	  prevalence	  of	  resting	  
LV	  outflow	  tract	  obstruction.	  	  
The	  arrhythmic	  risk	  of	  HCM	  has	  been	  known	  since	  the	  first	  reports	  
of	  the	  disease	  in	  the	  fifties.	  With	  time,	  due	  to	  the	  increasing	  knowledge	  of	  
the	   complexity	   of	   this	   cardiomyopathy,	   many	   other	   features	   of	   the	  
disease	   have	   been	   described	   and	   ventricular	   arrhythmias	   are	   now	  
considered	  only	  part	  of	  a	  heterogeneous	  spectrum	  of	  characteristics,	  with	  
an	   incidence	   of	   sudden	   cardiac	   death	   of	   1%/year	   in	   non	   selected	  
populations.	   The	  arrhythmogenic	  burden	  and	   the	   risk	  of	   sudden	  cardiac	  
death	   of	   thin	   filament	   mutations	   have	   always	   gained	   most	   of	   the	  
attention.	   Indeed,	   our	   results	   are	   consistent	   with	   previous	   reports	   of	  
enhanced	   arrhythmic	   propensity	   associated	   with	   thin	   filament	   HCM.	   In	  
our	  cohort,	  the	  annual	  rate	  of	  major	  arrhythmic	  events,	  including	  sudden	  
cardiac	   death,	   resuscitated	   cardiac	   arrest	   and	   appropriate	   ICD	  
intervention,	   was	   almost	   double	   that	   of	   the	   thick	   filament	   group	  
(2%/year).	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Figure	  2.1-­‐2:	  Phenotypic	  variability	  in	  thin	  filament	  HCM.	  	  
	  (A-­‐H)	  Echocardiographic	  apical	  4-­‐chamber	  views	  showing	  different	  
patterns	  of	  distribution	  of	  hypertrophy	   (ID	  number	  and	  mutation	  
for	  each	  patient	  are	  reported).	  	  
	  (A-­‐B)	   Mild-­‐to-­‐moderate	   hypertrophy,	   with	   “classical”	   septal	  
localization	  of	  maximal	  LV	  thickness.	  	  
	  (C)	  Moderate	  septal	  hypertrophy	  with	  apical	  involvement;	  	  
	  (D)	  mid-­‐apical	  septal	  hypertrophy;	  	  
	  (E)	   moderate	   mid-­‐septal	   hypertrophy	   with	   severe	   left	   atrial	  
dilatation;	  	  
	  (F)	  mild	  concentric	  hypertrophy	  	  
	  (G)	  apical	  hypertrophy	  with	  severe	  left	  atrial	  dilatation;	  	  
	  (H),	  moderate	  concentric	  hypertrophy	  with	  severe	  apical	  involvement	  
and	   marked	   bi-­‐atrial	   enlargement.	   (I)	   Echocardiographic	   and	   cardiac	  
magnetic	   resonance	   (CMR)	   images	   from	   a	   patient	   with	   the	   TNNT2-­‐
R92W	  mutation.	   From	   left:	   apical	   four-­‐chamber	   and	   parasternal	   long	  
